COGNITION THERAPEUTICS INC (CGTX) Stock News

NASDAQ:CGTX - Nasdaq - US19243B1026 - Common Stock - Currency: USD

0.7545 +0.08 (+11.45%)

After market: 0.751 0 (-0.46%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CGTX Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: The Motley Fool

Cognition (CGTX) Q2 Grant Income Jumps

3 days ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

3 days ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs

12 days ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

12 days ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

20 days ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

25 days ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

a month ago - By: Yahoo Finance - Mentions: UNIT

Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress

a month ago - By: Benzinga - Mentions: LIXT MREO RARE CELZ ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a month ago - By: Benzinga - Mentions: IGC AEMD MREO RARE ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

a month ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

2 months ago - By: Cognition Therapeutics, Inc.

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

2 months ago - By: Cognition Therapeutics, Inc.

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

2 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

3 months ago - By: Cognition Therapeutics, Inc.

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health